Clinical Journal of the American Society of Nephrology

Semaglutide effects showed no clear racial or ethnic differences

An exploratory randomized-trial analysis included 3,454 participants with race data and 3,388 with ethnicity data, all with chronic kidney disease and type 2 diabetes.

Paper by Carlos Campos, Richard E. Pratley, Sherif J. Mehanna, +7 more authorsChristian W. Mende · Diabetes Care Center · University of California San Diego
Kidney cross-sections show similar contrasts of preserved dark blue-green tissue and scarred gray tissue beside two groups of small upright figures.
Studied:
Randomized trial in 3,454 people with chronic kidney disease and diabetes, median 3.4 years (Placebo-controlled)
What changed:
Semaglutide’s effects on kidney outcomes, cardiovascular events, and death did not clearly differ across racial or ethnic groups
The catch:
Racial and ethnic treatment comparisons were exploratory subgroup analyses conducted after the fact

Editor of record: Boris Djordjevic · AgingResearch.News

Follow @agingbrief

The 3,533 participants in the international FLOW randomized controlled clinical trial had chronic kidney disease and type 2 diabetes. A post hoc exploratory analysis, which revisited the trial data, compared once-weekly injections of semaglutide 1.0 mg with placebo, both added to standard care. The main outcome counted kidney failure, a sustained fall of at least 50% in estimated kidney filtering capacity, or death from kidney-related or cardiovascular causes.

The analysis compared Black/African American with non-Black/African American participants, and Hispanic/Latino with non-Hispanic/Latino participants. Over a median 3.4 years, it found no statistical evidence that treatment effects differed between these groups for the main outcome, major cardiovascular events, death from any cause or annual change in kidney function.

Why it matters

For age-related conditions such as type 2 diabetes, understanding variation in treatment response matters when weighing kidney, cardiovascular and survival outcomes.

Caveats

The exploratory subgroup analysis could miss differences, especially with only 160 Black/African American participants; no clear difference does not establish equal effects. The findings concern people with both chronic kidney disease and type 2 diabetes.

Comments

Be the first to comment.